See more : Samse SA (SAMS.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Rapid Therapeutic Science Laboratories, Inc. (RTSL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rapid Therapeutic Science Laboratories, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- CureVac N.V. (5CV.F) Income Statement Analysis – Financial Results
- Osage Exploration and Development, Inc. (OEDVQ) Income Statement Analysis – Financial Results
- Melcor Developments Ltd. (MRD.TO) Income Statement Analysis – Financial Results
- Leadtek Research Inc. (2465.TW) Income Statement Analysis – Financial Results
- eGuarantee, Inc. (8771.T) Income Statement Analysis – Financial Results
Rapid Therapeutic Science Laboratories, Inc. (RTSL)
About Rapid Therapeutic Science Laboratories, Inc.
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.
| Metric | 2022 | 2021 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 534.00 | 9.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 200.00 | 7.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 334.00 | 1.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 62.55% | 21.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.24M | 2.11M | 169.69K | 135.68K | 21.62K | 12.02K | 12.30K | 18.96K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.24M | 2.11M | 169.69K | 135.68K | 21.62K | 12.02K | 12.30K | 18.96K |
| Other Expenses | 23.97K | 55.86K | 0.00 | 16.39K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.26M | 2.17M | 169.69K | 152.08K | 21.62K | 12.02K | 12.30K | 18.96K |
| Cost & Expenses | 1.26M | 2.17M | 169.69K | 152.08K | 21.62K | 12.02K | 12.30K | 18.96K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.90M | 1.33M | 180.53K | 28.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 23.97K | 55.86K | 1.38K | 16.39K | 22.82K | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.24M | -2.11M | -169.69K | -135.68K | -21.62K | -12.02K | -12.30K | -18.96K |
| EBITDA Ratio | 0.00% | -395,961.80% | -1,856.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.26M | -2.17M | -169.69K | -2.52M | -21.62K | -12.02K | -12.30K | -18.96K |
| Operating Income Ratio | 0.00% | -406,422.28% | -1,856.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -531.39K | -697.59K | 1.38K | -2.37M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -1.79M | -2.87M | -348.84K | -2.55M | -21.62K | -12.02K | -12.30K | -18.96K |
| Income Before Tax Ratio | 0.00% | -537,056.74% | -3,817.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -100.92K | 1.33M | -1.38K | 28.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -1.69M | -4.20M | -348.84K | -2.55M | -21.62K | -12.02K | -12.30K | -18.96K |
| Net Income Ratio | 0.00% | -786,015.73% | -3,817.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.22 | -0.55 | -7.24 | -25.88 | -0.20 | -0.11 | -0.11 | -0.17 |
| EPS Diluted | -0.22 | -0.55 | -7.24 | -25.88 | -0.20 | -0.11 | -0.11 | -0.17 |
| Weighted Avg Shares Out | 7.75M | 7.63M | 48.16K | 98.64K | 108.40K | 108.40K | 108.40K | 108.40K |
| Weighted Avg Shares Out (Dil) | 7.75M | 7.63M | 48.16K | 98.64K | 108.40K | 108.40K | 108.40K | 108.40K |
Rapid Therapeutic Science Laboratories to Present at the Q4 Investor Summit Conference
Source: https://incomestatements.info
Category: Stock Reports